With many successes and key moments to reflect on, it is nearly impossible to recap all in a single post. Instead, you can hear favorite moments directly from the 14 members of the T1International team! Read more
Voices from around the world were part of the T1International Rally and March outside Eli Lilly on October 24th, where #insulin4all activists demanded Eli Lilly immediately lower the list price of insulin and defended the lives of those who are rationing insulin just to survive. Read more
A recent study of 2021 National Health Interview Survey data demonstrates what #insulin4all advocates have been saying for years: too many people are dangerously rationing insulin due to cost. While insulin costs around $6 to manufacture, three companies dominate more than 90% of the insulin market and charge around $300 for a single vial of insulin. Read more
T1International’s virtual #insulin4all Summit, Health is Wealth, was held on September 24th. Thank you everyone for your participation and read our recap here! Read more
The journey to move towards a federal insulin price cap has been long and difficult, including challenging incremental steps. The fight for a true insulin price cap in the US continues. Read more
Misinformation about diabetes and insulin is all too regularly spread in both the media and on social platforms. In this post, we outline 5 of the most common talking points used to explain away price gouging and how we can use the facts to overcome this narrative. Read more
At the 75th World Health Assembly (WHA) of the World Health Organization (WHO), member states adopted the first ever ‘Global Diabetes Coverage Targets,’ meant to steer the course of diabetes diagnosis and treatment for the next 8 years. Read more
Take the Survey! The survey is for individuals over the age of 18 with type 1 diabetes. A parent or caregiver can take the survey for those under the age of 18. Caregivers can also take the survey for spouses or partners. The survey is anonymous and is completely optional. Read more
A report from Human Rights Watch powerfully illustrates the human impact of sky-high insulin prices through the testimony of 18 insulin-dependent people living with diabetes in the United States.
Read more
On Thursday, March 31st, the US House of Representatives voted to pass a $35 insulin copay cap. The bill now heads to the Senate. While a $35 copay cap on insulin would impact many people, T1International is calling on the Senate to pass a true price cap on insulin for everyone, especially those without insurance. Read more